Ultragenyx (RARE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $14.51 (+0.07%), Market cap $2.54B, 52-week low–high $18.50 ~ $41.44.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacuma
Financial statements, price targets, institutional (13F) holdings and related news for Ultragenyx are updated in real time on BlackAll Trade.
Ultragenyx trades at $14.51 (+0.07%). Real-time quotes and charts are available on BlackAll Trade.
Ultragenyx has a market cap of about $2.54B.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare g